Here are the S-3 shelf registrations from BeOne Medicines Ltd. (ONC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ONC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONC filings page.
BeOne Medicines Ltd. filed a post-effective Form S-3 shelf registration to replace an expiring registration, registering up to 398,880,905 Ordinary Shares, including 374,373,961 Ordinary Shares represented by 28,797,997 ADSs (each ADS = 13 Ordinary Shares). The prospectus states BeOne is not selling any shares here and will not receive proceeds; proceeds, if any, will go to the listed selling shareholders. The registration covers resale by Amgen, entities affiliated with Baker Bros. Advisors and HHLR Advisors under existing registration rights. The filing notes cross‑listings on HKEx, Nasdaq and the STAR Market and highlights business, liquidity and China‑related operational risk disclosures incorporated by reference.
BeOne Medicines Ltd. files a new shelf registration on Form S-3 to replace an expiring registration and permit, from time to time, primary offerings and resales of ordinary shares, ADSs, preferred shares, debt securities, warrants and units.
The shelf contemplates offerings by the company and selling shareholders, with proceeds to the company disclosed only in future prospectus supplements; the company discloses key context figures including $731 million in cash and cash equivalents as of March 31, 2026, approximately 1,540,975,898 Registered Shares issued, and recent product and pipeline highlights (BRUKINSA sales of $3.9 billion in 2025). The registration replaces an earlier S-3 that would expire on May 9, 2026.